Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Xenoport Inc (NASDAQ:XNPT)

Delayed Data
As of Nov 27
 +0.10 / +1.56%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. The company's first product gabapentin enacarbil which is known as Horizant in United States and Regnite in Japan, is developed for the treatment of moderate-to-severe primary restless legs syndrome in adults. The XenoPort holds all other world-wide rights and has co-promotion and certain development rights to gabapentin enacarbil in the United States. The company's pipeline of products candidates includes potential treatments for patients with Postherpetic Neuralgia, Spasticity and Parkinson's disease. XenoPort was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on May 19, 1999 and is headquartered in Santa Clara, CA.

Contact Information

XenoPort, Inc.
3410 Central Expressway
Santa Clara California 95051
P:(408) 616-7200
Investor Relations:
(408) 616-7220



Individual stakeholders9.34%
Other institutional64.22%
Mutual fund holders28.91%

Top Executives

Vincent J. AngottiChief Executive Officer & Director
William G. HarrisChief Financial Officer & Senior VP-Finance
Richard K. KimChief Medical Officer & SVP-Clinical Development
Jacqueline CossmonSenior Director-Investor Relations
Richard A. FarleyVice President-Human Resources